Navigation Links
Bacterin Secures $25 Million Financing with OrbiMed
Date:8/28/2012

BELGRADE, Mont., Aug. 28, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of unique bone graft material and antimicrobial coatings for medical applications, announced the closing of a $25 million non-dilutive financing with an affiliate of OrbiMed Advisors LLC.  The financing will enable Bacterin to execute its growth strategy through anticipated profitability.

Under the terms of the agreement, Bacterin initially received $20 million and has the ability to draw down an additional $5 million based upon the achievement of mutually agreed upon revenue objectives prior to December 31, 2013.  The Company received net proceeds of approximately $10 million after repayment of existing indebtedness as well as other transaction related fees and expenses.  Net proceeds will be used by the Company for general working capital purposes. No equity securities or warrants were issued as part of the transaction.

"Today's funding marks an important milestone for the Company as we entered into a financing agreement with OrbiMed.  With this financing, we don't anticipate the need for additional working capital in our pursuit of achieving profitability," said Guy Cook, Chairman and CEO of Bacterin. "OrbiMed's recognition of Bacterin's unique technology and strong growth profile enabled us to secure this non-dilutive financing option. The future and long-term opportunity for Bacterin products, in multi-billion dollar addressable markets, is today stronger than ever."

"We are very pleased to partner with Bacterin and offer a non-dilutive capital solution to help the Company execute its growth strategy," said Tadd Wessel, a Managing Director on the Royalty Opportunities team at OrbiMed. "Bacterin has made substantial progress with the commercialization of their biologics platform and we look forward to w
'/>"/>

SOURCE Bacterin International Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
2. Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year
3. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
4. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
5. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
6. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
7. Generex Secures Commitments for $3.6M Capital Raise
8. Roka Bioscience Secures $47.5 Million in Series D Financing
9. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
10. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
11. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... -- Research and Markets  has announced ... Report 2014" report to their offering. ... Palmitic Acid Industry Report 2014 is a professional and ... palmitic acid industry. The report provides a ... and industry chain structure. The palmitic acid market analysis ...
(Date:11/26/2014)... 21, 2014 (PRWEB) November 26, 2014 ... communications network, today announced the organization has won a ... Club Awards. Digitas Health LifeBrands was honored with a ... other PHCG agencies received eight Awards of Excellence. ... aspects of pharmaceutical advertising and promotion. The Awards provide ...
(Date:11/26/2014)... The announced sales of three healthcare units ... to expand in non-healthcare areas, says Kalorama Information. Siemens ... firm says that  Siemens is the third largest company ... the IVD market , with 5.5 billion in IVD ... would likely affect IVD market shares.  ...
(Date:11/26/2014)... PMG Research, Inc. announced today the ... network of sites that provide clinical research services to pharmaceutical ... lives through its partnerships with large physician practices and integrated ... locations in the Southeastern United States and spans over 60 ... board will be held by: Dr. Robert Holmes, MD, ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 27 PDL BioPharma, Inc. (PDL, ... it has entered into separate privately negotiated exchange agreements under ... the Company,s outstanding 2.00% Convertible Senior Notes due February 15, ... holders of the 2012 Notes will receive $92.0 million in ...
Cached Biology Technology:Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 2Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 3Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 4Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 5Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 6Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 7Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 8The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 2PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 3
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... With only two weeks to go and almost a ... 2013 have reached their final stages. This year,s conference ... Simons will deliver the opening keynote lecture and explain ... cells work. In further keynote lectures, Hans Clevers will ...
... 9, 2013 Cytos Biotechnology Ltd (SIX:CYTN) today ... CYT003, a first-in-class immune modulator in clinical development as a ... data published in the March issue of The Journal ... at the European Respiratory Society Annual Congress in ...
... 2013 Disease-causing bacteria stink literally and the ... the basis for a faster and simpler new way to ... here today at the 246th National Meeting & Exposition of ... The new test produces results in 24 hours, compared ...
Cached Biology News:All set for The EMBO Meeting 2013 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 4Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 5New 'artificial nose' device can speed diagnosis of sepsis 2
EML1 (K-16)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Biology Products: